A Single-Arm Trial of Hematopoietic Stem Cell Transplantation-Supported Dose-Dense Chemotherapy with Adebrelimab As First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer

The goal of this clinical trial is to learn if hematopoietic stem cell transplantation-supported dose-dense chemotherepy with adebrelimb works to treat extensive-stage small-cell lung cancer in adults. It will also assess the safety of this treatment approach.
The main questions it aims to answer are:
Does hematopoietic stem cell transplantation-supported dose-dense chemotherepy with adebrelimb improve the median progression free survival and 12-months overall survival rates? What medical problems do participants experience whild undergoing this treatment?
Participants will:
Complete two 21-days cycles of standard-dose etoposide and carboplatin, followed by G-CSF for stem cell mobilization.
Receive dose-dense chemotherapy followed by autologous stem cell reinfusion for two 21-day cycles.
If eligible, participants will receive etoposide and carboplatin plus adebrelimab for four cycles.
Finally, participants may enter a maintenance phase with adebrelimab.
Throughout the trial, participants will:
Visit the clinic every 21 days for check-ups and tests. Imaging examination every 6 weeks. Followed up by telephone every 2 months

开始日期2024-12-01

申办/合作机构

广州呼吸疾病研究所

NCT06645210 / Not yet recruitingN/AIIT

A Multicenter Retrospective Cohort Study on Allergic Bronchopulmonary Aspergillosis

To understand the current diagnosis and treatment status of ABPA patients, observe their clinical characteristics, prognosis, and treatment outcomes, and identify the relevant factors for poor prognosis in patients.

开始日期2024-10-15

申办/合作机构

北京大学第三医院

[+13]

NCT06603207 / Not yet recruitingN/AIIT

Causal Association Between Rheumatoid Arthritis and Periodontitis: A Mendelian Randomization Study

This study aims to investigate the causal relationship between rheumatoid arthritis and periodontitis using Mendelian randomization. Data will be sourced from genome-wide association studies (GWAS) to explore genetic associations and assess potential risk factors in an East Asian population.

开始日期2024-10-01

申办/合作机构

广州呼吸疾病研究所

[+1]

100 项与广州呼吸疾病研究所相关的临床结果

登录后查看更多信息

0 项与广州呼吸疾病研究所相关的专利（医药）

登录后查看更多信息

355

项与广州呼吸疾病研究所相关的文献（医药）

2024-05-01·BMJ Open Respiratory Research

Prevalence, Medicaid use and mortality risk of low FEV₁in adults aged 20–35 years old in the USA: evidence from a population-based retrospective cohort study

Article

作者: Zheng, Jinping ; Zhong, Nanshan ; Wang, Zihui ; Lin, Junfeng ; Huang, Jinhai ; Liang, Lina ; Zhang, Qing ; Li, Yun ; Liu, Shuyi ; Gao, Yi ; Tan, Lunfang ; Wang, Zhufeng

BackgroundThe prevalence, Medicaid use and mortality risk associated with low forced expiratory volume in 1 s (FEV1) among young adults aged 20–35 years are not well understood, despite its potential implications for the development of chronic pulmonary disease and overall prognosis.MethodsA retrospective cohort study was conducted among young adults aged 20–35 years old, using data from the National Health and Nutrition Examination Survey, National Death Index and Centers for Medicare & Medicaid Services. Participants were categorised into a low FEV1group (pre-bronchodilator FEV1%pred <80%) and a normal FEV1group (FEV1%pred ≥80%). Weighted logistic regression analysis was employed to identify the risk factors associated with low FEV1, while Cox proportional hazard models were used to calculate the hazard ratio (HR) for Medicaid use and the all-cause mortality between the two groups.ResultsA total of 5346 participants aged 20–35 were included in the study, with 329 in the low FEV1group and 5017 in the normal group. The weighted prevalence of low FEV1among young adults was 7.1% (95% CI 6.0 to 8.2). Low body mass index (OR=3.06, 95% CI 1.79 to 5.24), doctor-diagnosed asthma (OR=2.25, 1.28 to 3.93), and wheezing or whistling (OR=1.57, 1.06 to 2.33) were identified as independent risk factors for low FEV1. Over a 15-year follow-up, individuals in the low FEV1group exhibited a higher likelihood of Medicaid use compared with those in the normal group (HR=1.73, 1.07 to 2.79). However, there was no statistically significant increase in the risk of all-cause mortality over a 30-year follow-up period (HR=1.48, 1.00 to 2.19).ConclusionsA considerable portion of young adults demonstrated low FEV1levels, a characteristic that was associated with a higher risk of Medicaid use over a long-term follow-up, yet not linked to an augmented risk of all-cause mortality.

2024-02-01·Quantitative Imaging in Medicine and Surgery

Investigation of the correlation between the change in the projected lung area and forced vital capacity using biphasic chest dynamic digital radiography: a cross-sectional study

Article

作者: Lan, Rihui ; Brunelli, Alessandro ; Song, Yuquan ; Li, Xian ; Liu, Chunli ; Ouyang, Lechuan ; Li, Qianyi ; Chen, Qiongzhu ; Xia, Ziyang ; Kim, Seong-Hyop

BackgroundChest dynamic digital radiography (DDR) is used as a supplementary tool for the routine pulmonary function test (PFT); however, its potential as a novel standard PFT method has yet to be explored. Therefore, the present study aimed to investigate the correlation between the change in the projected lung area (ΔPLA) and forced vital capacity (FVC) using chest DDR, and to establish a DDR-FVC estimation model and a predictive value model for the ΔPLA.MethodsIn total, 139 participants who underwent chest DDR and the PFT in the same period at The First Affiliated Hospital of Guangzhou Medical University from April 2022 to February 2023 were prospectively included in the study. The patients' age, gender, height, and weight measurements were recorded. Additionally, the ΔPLA was measured, and the IWS workstation software was used for automated outlining and calculation. Subsequently, a correlation analysis and regression analysis models were employed to examine the relationship between the ΔPLA, FVC, and individual physiological characteristics. Additionally, an independent sample t-test was used to determine whether there were any significant differences between the normal and abnormal FVC groups.ResultsThe 139 participants were grouped according to the results of the ratio of measured/predicted FVC values (FVC%pred); those with an FVC%pred ≥80%, were allocated to the normal FVC group, and those with an FVC%pred <80% were allocated to the abnormal FVC group. The correlation coefficient was >0.8 in the full sample; the ΔPLA showed a significant linear correlation with the measured FVC value [r=0.81, 95% confidence interval (CI): 0.75-0.86, P<0.001]. There was a significant difference in the ΔPLA between the normal and abnormal FVC groups. With the ΔPLA, age, gender, height, and weight as predictor variables, the following DDR-FVC estimation model was established: DDR-FVC estimation model = -0.997 + 1.35×10^-4 × ΔPLA + 0.017 × height - 0.014 × age + 0.249 × gender (1 for male and 0 for female) [adjusted R² (adj. R²)=0.731, F=94.615, P<0.001]. The following formula was used to determine the predictive value of the ΔPLA: Predictive value of ΔPLA = -12,504.287 + 173.185 × height + 62.971 × weight - 84.933 × age (adj. R²=0.393, F=20.453, P<0.001).ConclusionsThere was a linear correlation between the ΔPLA measured by biphasic chest DDR and the FVC. A model for estimating the FVC was established based on the ΔPLA, which allows the FVC to be assessed by the ΔPLA measured by biphasic chest DDR. A predictive value model for the ΔPLA was also established to provide ΔPLA reference values for assessment and comparison.

2023-03-23·BMJ open

Influencing factors of health resource allocation and utilisation before and after COVID-19 based on RIF-I-OLS decomposition method: a longitudinal retrospective study in Guangdong Province, China.

Article

作者: Xu, Jun ; Wu, Qiaohui ; Liang, Xueqing ; Xue, Yunlian ; Wu, Linjian ; Wu, Weixuan

OBJECTIVESTo explore factors that influenced the health resource allocation and utilisation before and after COVID-19, and subsequently offer sensible recommendations for advancing the scientific distribution of health resources.DESIGNA longitudinal survey using 2017-2020 data, which were collected for analysis.SETTINGThe study was conducted based on data collected from the Health Commission of Guangdong Province's website.OUTCOME MEASURESEight health resource indicators and four health resource utilisation indicators were included in the factor analysis. Four indices were calculated to measure the inequality in health resource allocation and utilisation. We analysed factors for the inequality indices using the recentred influence function index ordinary least squares decomposition method.RESULTSThe health resource inequality indices peaked in 2020 (Gini coefficient (Gini): 0.578, Absolute Gini coefficient (AGini): 1.136, Concentration Index (CI): 0.417, Absolute CI (ACI): 0.821), whereas the health resource utilisation inequality indices declined year by year, thus reaching their lowest point in that same year. The majority of inequality indices in the annual change of health resource allocation were at their lowest in 2020 (Gini: -1.672, AGini: 0.046, CI: -0.189, ACI: 0.005), while the use of health resources declined dramatically, showing a negative growth trend. The inequality indices of health resource allocation and utilisation in 2020 were affected by a number of variables, including the COVID-19 level, (p<0.05), while the proportion of expenditure on public health was the most significant one.CONCLUSIONSGuangdong Province's health resource allocation and utilisation were still concentrated in economically developed regions from 2017 to 2020. The health resource allocation inequality indices increased, especially under COVID-19, but the health resource utilisation inequality indices decreased. Measures should be taken to adjust the health resource allocation scientifically, which will fulfil the changing needs and the use of resources more efficiently. One effective measure is reasonably increasing the proportion of expenditure on public health.

项与广州呼吸疾病研究所相关的新闻（医药）

2023-09-18

·BioBAY

官宣！信迈医疗支气管射频消融系统治疗重症持续性哮喘注册临床试验（BATA Study）完成全部患者入组

8月23日，苏州信迈医疗科技股份有限公司（以下简称：信迈医疗）宣布其开展的支气管射频消融系统治疗重症持续性哮喘的注册临床试验（BATA Study：Bronchial Ablation For Treatment of Asthma Trial；NCT03765307）顺利完成全部患者入组（n=163）。据统计，我国哮喘患者患病率逐年上升，预计到2025年，我国哮喘患病人数将达到约7540万人，其中重度哮喘患者约为536万人。然而，国内目前使用的支气管射频消融系统完全依靠进口，不但高昂的医疗费用往往使患者望而却步，其消融导管的设计及消融控制程序与中国患者的特异性和需求有差异。BATA试验成功完成全部患者入组，标志着信迈医疗支气管射频消融系统在国产医疗器械替代和再创新上又迈出了重要一步，为我国中、重症哮喘患者带来了新希望，具有重要的临床和社会意义。信迈医疗的BATA试验由广州呼吸疾病研究所副所长、广州医科大学第一附属医院呼吸内科学科主任李时悦教授担任主要研究者，全国15家医院和呼吸领域知名专家参与：广州医科大学第一附属医院张清玲教授、中国科学院大学深圳医院龙发教授、上海市第十人民医院王昌惠教授/宋小莲教授、河北医科大学第二医院阎锡新教授/蔡志刚教授、齐齐哈尔医学院附属第三医院石寒冰教授、江苏省人民医院姚欣教授/赵欣教授、苏北人民医院徐兴祥教授/许文景教授、浙江大学医学院附属第二医院徐浩教授、中国人民解放军总医院第一医学中心陈良安教授、中国人民解放军空军军医大学第二附属医院李王平教授、苏州市立医院徐晓教授/林盪教授、中国人民解放军北部战区总医院马壮教授、河北省胸科医院李幸彬教授、徐州医科大学附属医院陈碧教授/刘平莉教授、烟台毓璜顶医院邹慎春教授。广州医科大学第一附属医院中国科学院大学深圳医院河北医科大学第二医院河北省胸科医院江苏省人民医院齐齐哈尔医学院附属第三医院上海市第十人民医院苏北人民医院苏州市立医院本部苏州市立医院东院唐都医院徐州医科大学附属医院浙江大学医学院附属第二医院试验相继完成入组（左右滑动查看更多）BATA试验采用了前瞻性、多中心、随机、对照、单盲（随访医生和患者）的设计，旨在评估信迈Elation®支气管射频消融系统在严重哮喘患者中的安全性和有效性。受试者为在高剂量吸入糖皮质激素（ICS）和长效β2-肾上腺素激动剂（LABA）治疗下仍然有症状的重度哮喘患者，主要终点为两组患者（信迈组 vs 友商支气管射频消融治疗组）在支气管射频消融治疗后12个月时，一年内哮喘重度急性发作率（每人每年发作次数）差异。次要终点为：1.两组患者在支气管射频消融治疗后3、6、12个月时，哮喘生活质量问卷调查（AQLQ: Asthma Quality of Life Questionnaire）评分的平均值（Integrated AQLQ）相对于基线的变化差异；2.AQLQ评分；3.ACQ-6评分（ACQ: Asthma Control Questionnaire）；4.无哮喘症状日的百分比；5.哮喘重度急性发作次数第一秒用力呼气量：FEV1（Forced Expiratory Volume in 1 Second）。该试验由著名CRO杰诺医学团队与信迈医疗共同运营管理，杰诺医学以其丰富经验和专业能力，进一步保障了试验的质量和进度。数据管理和统计工作由国家心血管病中心医学统计部的李卫教授团队承担，团队的专业素养、严谨的态度和杰出的业界声誉为试验数据的真实有效提供了强有力的支持。支气管消融术又称支气管热成形术（Bronchial Thermoplasty，BT），是全球哮喘防治指南GINA，以及我国哮喘治疗指南推荐的唯一可用于治疗重度哮喘的非药物治疗方式。其原理是借助射频热能直接作用于气道壁，消融患者气道内病理性增生的平滑肌，缓解气道阻力，降低气道痉挛的发生，从而减轻哮喘症状。临床循证医学数据证实了这一疗法十年的有效性和安全性。李时悦教授：“BT疗效可持续十年或以上并且具有良好的安全性，BT可以推荐作为哮喘治疗的一种非药物、长效治疗方法，尤其对于充分的药物治疗仍然无法控制的哮喘患者或者对于生物制剂无应答的患者。”龙发教授：“BT疗法可以减少重度哮喘患者的急性发作，对提高患者生活质量有着重要的临床意义，如果用于这一治疗的设备和器械能够国产化，改变目前价格昂贵的状况，将在临床上产生良好的应用前景，使更多的病人获益。”宋小莲教授：“我国的呼吸介入已经从学习国外进入到自主研发和赶超的新阶段，热成形治疗也是国产器械研发比较早的一个领域，由于既往在热成形治疗过程当中遇到的种种问题，信迈医疗针对国人气道的特点，对仪器、耗材等做了一些修改，使得导管的可塑性更强，气道的贴壁性及贴壁的感知性都更加友好；随着设备国产化，相信在经济学方面也会有更大的优势。”阎锡新教授：“BT技术在临床医学的开展为重症、难治性支气管哮喘患者打开了一扇门，使一部分无法脱离激素治疗的患者减少了激素的使用，降低了患者急性加重的频次。高端医疗设备器械的国产化，能够让更多的哮喘患者接受BT疗法这类高端微创的治疗方式，为他们带来更多获益。”石寒冰教授：“非常感谢李时悦教授、信迈医疗牵头开展BATA试验，能有这么好的难得的机会，不仅使患者大大受益，对我们学科的介入领域也是一个扩展。相信随着国产器械的崛起和医保的逐步覆盖，随着临床数据和经验进一步累积，我觉得未来BT疗法前景很广阔，将会实实在在地惠及患者。”信迈医疗专注于研发与应用突破性创新微创介入技术治疗心血管和呼吸领域重大疾病，其具有知识产权保护、自主研发生产的Elation®支气管射频消融系统，是唯一进入国家药品监督管理局创新医疗器械特别审查程序（“绿色通道”）的用于治疗哮喘的支气管消融产品，这一系统具有以下优势：使用了独创全新、并受到专利保护的微调渐进式射频能量传递/反馈控制策略，优化拟合了消融关键参数如能量、温度、阻抗、电流之间的变化反馈曲线，使支气管消融的安全性和有效性得到进一步提高；自动检测网篮状的4电极是否贴壁良好，以便术者判断是否实施了有效消融，保证了更好的人机问答；导管头端电极直径更小，更适合于国人的肺部解剖特征，更为合理的电极材料选用和处理而保证了电极的可操作性和通过性，可更容易到达气管内壁病灶；对导管头端网篮状电极材料做特殊处理和优化设计，避免了市场上现有导管在使用中经常出现的导管网状电极变形和不张的情况。虽然国内已经引进支气管射频消融治疗设备多年，但手术的渗透率在目标人群中仍然较低，其中的主要原因是进口器械给患者造成了巨大的经济负担，严重阻碍了这一疗法的推广和应用。因此，国产化产品的出现具有重要意义，期待未来信迈医疗的BATA试验积累更多临床数据，为更多患者带来获益。延伸阅读专访｜龙发：“呼吸”“介入”一相逢，便胜却人间无数专访｜宋小莲：BT术的出现，开启慢性气道疾病呼吸介入治疗的新纪元专访｜阎锡新、蔡志刚：谨慎常在，行有所止，让支气管热成形术蓬勃在一呼一吸之间专访｜石寒冰：支气管热成形术让重症哮喘患者迎来治疗的春天专访｜徐兴祥：打破呼吸枷锁支气管热成形术满足重症哮喘患者未尽之需· END ·本文内容为“严道医学”发布转载发布须经授权并注明出处获取更多资讯，点击 “阅读原文” 下载 “严道医声APP”

2022-07-29

·丁香园

吃最辣的火锅，住最好的肛肠科：全国医院排名会被食物影响吗？

本文作者：关麟近些年来，互联网上一直流传着这样一个段子：在川渝地区，一家火锅店的好吃程度，基本取决于周边肛肠科医院的密集程度——「吃最辣的火锅，住最好的肛肠科」。为了世界和平，此处我们不便继续展开讨论究竟哪个城市的火锅最辣。图片来源：自己吃的虽然段子只是段子，但也在一定程度上反应了如今专科排名的情况。医院的专科排名是一门复杂的学问，如雷贯耳的大医院均衡发展也就罢了，为什么有些三四线城市的医院，也有专科能做到全国前列？这就归结到本文的中心思想：医院专科的发展水平，到底受哪些因素影响？阅前声明，为了拉平医院专科水平的评价标准，我们优先选取复旦专科声誉榜作为参考，结合学术论文、新闻报道、日常认知进行分析。地方病促成由于灵感来自于一顿火锅，我们不妨将其命名为「火锅分析」。令人稍感意外的是，根据《我国居民常见肛肠疾病相关症状及分布特征》，我国西南地区肛肠疾病的症状发生率为 37.37%，低于华中地区的 45.40%，更低于华南地区的 51.69%。也正因如此，反映在专科上，无论是复旦排行，还是丁香医生的就诊智能推荐，名单中的医院都显得十分「情理之中」。只有华西医院位于四川图片来源：复旦排行榜但得益于这顿火锅的启发，我们可以从真正的地方性疾病中发现，它对地区医学专科实力的影响。以东北地区的心脑血管疾病为例。在 2019 年时，Nature 子刊曾有文章讲述过我国心血管病流行的特点，其中指出，与华南相比，东北的卒中发病率要高出 2.4 倍，且死亡率高出 1.4 倍。图片来源：Epidemiology of cardiovascular disease in China: current features and implications 而在 2020 年的复旦专科榜中，哈医大附属二院赫然在列。图片来源：复旦排行榜早在 2008 年，哈医大二院心内科成为原卫生部首批东三省唯一一家包含冠心病、心律失常、先心介入治疗的培训基地。哈医大二院胸痛中心是通过中国胸痛中心认证委员会的认证全国十家胸痛中心之一，急性心肌梗死的院内急救达到了国际先进水平。建立院前、院内、出院后一体化、无缝衔接的急性胸痛救治体系。充分体现了「时间就是心肌，时间就是生命」的心肌梗死治疗理念。据哈医大二院官网介绍，该院心内科是国家重点专科全国第九、东北第一，2013、2014 年挺进复旦大学心血管专科排名全国前十名。现为东三省医学院校附属的最大的心血管病治疗中心，也是全国有影响的心血管病治疗中心之一。专家带飞而专科排行榜上另一种让人无法忽视的黑马，则是由专家一己之力带飞的团队。首屈一指的是呼吸内科的广州医科大学附属第一医院，而该医院最为知名的专家，便是钟南山院士。图片来源：复旦排行榜而根据广州呼吸疾病研究所官网介绍，正是在 2004 年，SARS 疫情过后，广州医科大学附属第一医院呼吸内科被评为国家重点学科；2005 年，经广东省科技厅批准，广州呼吸疾病研究所与中国科学院广州生物医药与健康研究院组建「广州呼吸疾病联合实验室」；2006 年，广州呼吸疾病联合实验室向科技部提出了筹建「呼吸疾病国家重点实验室」的申请。呼吸疾病国家重点实验室（SKLRD）是依托广州医科大学于 2007 年 10 月获国家科技部批准建设的我国呼吸疾病研究领域唯一的国家重点实验室。共建单位为广州呼吸健康研究院与中国科学院广州生物医药与健康研究院。实验室首任主任为钟南山院士，现任主任为冉丕鑫教授，学术委员主任为黎孟枫教授。鉴于现有培养体系，内科可以发展理论知识，而外科依赖老医生「传帮带」，于是更加容易出现「主任熊熊一窝」的现象。而从实际情况上来看，一直以来内科强势医院相对稳定，而外科强势的医院，学科带头人及其团队被挖走以后，则更加容易出现青黄不接的情况。辅助科室的崛起与之前的榜榜有黑马不同的是，在辅助科室排行榜上，从病理科、放射科、检验医学科到超声医学科，基本都是顶尖大医院首尾相望。辅助科室的发展离不开自身的钻研与努力。从客观条件上来看，顶尖大医院也为其提供了其他医院所不能提供的平台与优厚资源。以北京协和医院的放射科为例，该科自 2014 年以来连续 3 年蝉联中国医院专科声誉排行榜放射科第一名，目前科室在岗正式职工 121 人，包括诊断组、护理组、技术组、登记保管组，其中正高职称 12 人、副高职称 15 人，80% 以上的科室医师具有硕士以上学位。再来参观协和放射科的设备，二甲放射科医生看了会沉默，普通三甲的放射科医生看了也会流泪。据其官网介绍：「本学科拥有大型影像诊疗设备数十台，其中包括目前世界上最先进的双源 CT6 台，640 层 CT1 台，256 层 CT1 台，能谱 CT1 台，64 排螺旋 CT1 台、16 排螺旋 CT2 台、3T 超高场磁共振和 1.5T 磁共振以及永磁介入专用磁共振在内的磁共振成像仪 10 台、数字减影血管造影机 7 台、全数字胃肠造影机 4 台、全数字乳腺 X 线摄影机 3 台，双能 X 线骨密度仪 2 台，另有计算机 X 射线摄影(CR)、直接数字 X 射线摄影(DR)、激光相机等设备器材共计 40 余台。科室内 PACS 系统已全面应用，实现了数字化诊断及图像管理、存储及自助发放。」图片来源：协和官网截图大医院巨大的患者流量以及诊疗水平向辅助科室提出了更高的配套技术要求，相对的，投入的资源也是成倍的，辅助科室的地位上升，使其在诊疗环节中更加主动——最终形成良性循环。以复旦检验医学榜上的山大二院为例，据齐鲁晚报报道，山大二院检验医学中心下设临床生化科、临床免疫科、临床分子生物学实验室、临床微生物科、血液与体液检验科、急诊检验科、南部院区检验科共七个专业科室。同时，要求检验技师向检验医师转型，每月到临床交流，更多参与临床决策。国家队为什么阜外在心血管领域为什么能够傲视全国？这件事情可以一直追溯到 1956 年。 1956 年，中国医学科学院阜外医院（以下简称阜外医院）的前身中国人民解放军胸科医院成立。1962 年，医院兼称心脏血管系统疾病研究所形成院所一体化的心血管病专科医院，2004 年，卫生部心血管病防治研究中心成立。可以说，从吴英恺院士创办的那一刻起，阜外就注定是一家不那么简单的医院。背负着国家级使命的阜外，是世界上规模最大的心血管疾病诊治中心。据其官网介绍，2011 年，医院外科手术量和内科 PTCA 手术量创历史新高，全年共完成外科手术 10107 例、PTCA10649 例，成为世界仅有的内、外科手术量均突破万例的特大心血管疾病诊疗中心。至此，医院年手术量持续增长：2019 年全年门诊 801379 人次，急诊 31952 人次，急诊危重症抢救 24121 人次；实有床位 1275 张；出院 74519 人次，床位周转 58.45 次，床位使用率 101.31%，平均住院日 6.35 天，死亡率 0.18%。住院外科手术 14808 人次，内科介入手术 52720 例、射频消融 6915 例、永久起搏器植入术 2617 例。对于医学这门实践性学科来说，先天+后天不断投入的良性循环，注定了阜外在心血管领域领先全国其他医院几个身位。从创办至今，阜外已经培养了 6 名院士，22 名国家级、省部级有突出贡献专家，78 人享受政府特殊津贴。另辟蹊径在眼科学中，温州医科大学附属眼视光医院（具有温州总院、杭州院区）也十分引人注目。纵观整个复旦专科排行榜，该院也是少有的既非省会、也非一线城市的上榜医院。而没有了地域这一先天加成，温医大附属眼视光医院就只能另辟蹊径。图片来源：复旦排行榜温州医科大学是世界上首个创立眼视光医学专业的学校。据其医院官网介绍，眼视光高等教育从专业设计到专业建设过程非常具有前瞻性。从眼的「生物属性」和「光学属性」双重特性出发，在国际上首次将经典「眼科学」与现代「视光学」有机整合，提出视觉健康包括眼部疾病与视觉矫治康复两大部分，创建了归属于临床医学教育范畴的眼视光医学专业。图片来源：温州医科大学网站截图没有条件，创造条件也要上，从某种程度上来看，这很温州性格。不过归根结底，对于大多数医院来说，既没有那么多机遇也没有那么多挑战，医院的专科发展水平，还是扎扎实实的取决于医院投入的资源与精力。在春天认认真真地种下了多少小主治，在秋天就会收获多少大主任。（策划：Leu.）题图来源：自己拍的

放射疗法

2022-06-10

·PRNewswire

At 11% CAGR, Global Peptide Therapeutics Market Size is Expected to Reach USD 74 Bn by 2028 Says Zion Market Research - Industry Trends, Share, Value, Analysis & Forecast Report

NEW YORK, June 10, 2022 /PRNewswire/ -- As per the Zion Market Research study, The global peptide therapeutics market was valued at $35B in 2021 and is projected to grow at 11% CAGR during the forecast period & reach over $74B by 2028. The report analyzes the peptide therapeutics market's drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the global peptide therapeutics market. Key Industry Insights & Findings of the Peptide Therapeutics Market Reports: As per the analysis shared by our research analyst, the Peptide Therapeutics Market is expected to grow annually at a CAGR of around 11 % (2022-2028). Through the primary research, it was established that the Cognitive and Memory Enhancer Drugs Market was valued at approximately USD 35 Billion in 2021 and is projected to reach roughly USD 74 Billion by 2028. North America region is the hub of key pharmaceutical players, high technology, R&D investment capacity, and world-class cancer treatment facilities, making it a heavily contributing region in the global market. Europe is expected to show steady growth in the global market because of its advanced healthcare infrastructure and growing awareness related to peptide therapeutics. Africa & Latin America are expected to grow slowly owing to a lack of information on peptide therapeutics along with an absence of necessary healthcare infrastructure, resources, and treatment facilities. Zion Market Research published the latest report titled " Peptide Therapeutics Market By Route Of Administration (Parenteral, Oral, And Others), By Type (Innovative And Generic), By Type Of Manufacturers (In-House And Outsourced), By Type Of Molecule (Vasopressin, Somatostatin, Calcitonin, Immunopeptide, Natriuretic, And Others), By Technology (Liquid Phase, Solid Phase, And Hybrid Phase), By Application (Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease, And Others), And By Region: Global And Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, And Forecasts 2022 – 2028 " into their research database. Peptide Therapeutics Market: Overview Peptide therapeutics are naturally created disease-treating small chain amino acids known as peptides. They assist humans in hormone creation and are excellent at protecting from infections. Since peptide therapeutics are naturally created by the body, they do not have any side effects and are easily accepted by the body during medical treatments. Peptide therapeutics are century-old but were only known for their healing abilities. However, with technological advancements and extensive R&D, it was discovered that peptide therapeutics have extreme potential in treating severe diseases with great efficiency. The global peptide therapeutics market has a substantial presence in the field of acute respiratory disorders, endocrinology, oncology, metabolism disorders, diabetes, dermatology, gastroenterology, and sexual dysfunction. They are also used to treat cardiovascular diseases and bone diseases. Get a Free Sample Report with All Related Graphs & Charts (with COVID 19 Impact Analysis): Our Free Sample Report Includes: 2022 Updated Report Introduction, Overview, and In-depth industry analysis COVID-19 Pandemic Outbreak Impact Analysis Included 199 + Pages Research Report (Inclusion of Updated Research) Provide Chapter-wise guidance on Request 2022 Updated Regional Analysis with Graphical Representation of Size, Share & Trends Includes an Updated List of tables & figures Updated Report Includes Top Market Players with their Business Strategy, Sales Volume, and Revenue Analysis Zion Market Research methodology Industry Dynamics: Peptide Therapeutics Market: Growth Drivers Increase in cancer patients and respiratory disorders to propel the global market growth. The growing number of patients suffering from cancer and its after-effects is a leading global market driver. The most prevalent treatment for cancer involves chemotherapy and radiation which leave long-lasting impacts on the patients giving rise to requirements for substitutes like peptide therapeutics. This is expected to move the global peptide therapeutics market forward. Other chronic diseases like diabetes or cardiovascular diseases are also contributing to the global market growth. Rising demand for drugs that have minimal to no side effects like peptide therapeutics is attributed to becoming the global market driver during the forecast period. Exhaustive R&D on diseases that might raise global concerns and which can be treated by peptide therapeutics in the future is anticipated to drive the global market. Peptide Therapeutics Market: Restraints Unstable nature of peptide therapeutics likely to hamper market growth. Peptide therapeutics are extremely unstable rendering them difficult to be used. They can aggregate quickly resulting in damage to healthy cells. The volatility of peptide proteins is projected to act as a restraining factor for the global market growth. In most cases, peptide therapeutics cannot be administered orally. The invasive techniques used for the intake of peptide-based drugs may cause reluctance amongst certain sections of the global population and are anticipated to restrain the global market during the forecast period. Peptide therapeutics lack deep membrane permeability thus reducing the overall efficiency of the products, which is further anticipated to restrict the global market growth. Peptide therapeutics tend to oxidize under improper care. The easy oxidization of peptide proteins increases task tediousness and is expected to hamper the global market. Directly Purchase a Copy of the Report at Global Peptide Therapeutics Market: Opportunities Advent of multi-functional peptide therapeutics to bring growth prospects in the coming period. The global peptide therapeutics market has immense opportunities given the innumerable benefits of peptide-based drugs. The creation of multi-functional peptide therapeutics with an even wider array of use is anticipated to provide excellent growth opportunities in the global market. Increased innovation in alternate delivery modes of peptide therapeutics is expected to open multiple opportunities for the global market during the forecast period. Even though the presence of peptide therapeutics in the human body has been for more than a century, their discovery is a recent event. With every passing day more & more peptide therapeutics are added to the global market. As of 2022, there are more than 200 peptide therapeutics in the global market and with ongoing R&D, more are expected to be added soon. This is anticipated to open multiple growth opportunities in the global market. Global Peptide Therapeutics Market: Challenges Shift towards proteomics, high cost of peptide therapeutics along with quick expiration of patents to challenge the global market growth. The global market is expected to move toward the study of proteins also called proteomics to create substitutes for peptide-based drugs which is anticipated to challenge the global market growth during the forecast period. The development of peptide therapeutics is an expensive affair and the high cost of production & maintenance is anticipated to create challenging situations in the global market. The creation of novel drugs requires approval from regulatory bodies and the approval process is extremely stringent which is anticipated to become a challenging factor in the global market. A considerable number of patents for peptide therapeutics expire quickly which results in heavy losses to drug manufacturers and is anticipated to oppose the global market growth during the forecast period. Global Peptide Therapeutics Market: Segmentation The global peptide therapeutics market is segmented by route of administration, type, type of manufacturers, type of molecule, technology, application, and region Based on the route of administration, the global market is segmented into parenteral, oral, and others. Currently, the global market is led by the parenteral mode, however, the global market is anticipated to be led by the oral mode of administration, during the forecast period. Based on the type of manufacturers, the global market is segmented as in-house and outsourced. In-house manufacturing shares the highest market share and the same trend is anticipated during the forecast period, because of stringent rules laid down by regulatory bodies. Based on the type of molecule, the global market is segmented as vasopressin, somatostatin, calcitonin, immunopeptide, natriuretic, and others. Immunopeptide is projected to lead the global market share because of its effective use in the treatment of tumors and cancer. Based on technology, the global market is segmented into liquid phase, solid phase, and hybrid phase. The largest global market share was held by the liquid phase and is expected to continue with the same trend during the forecast period. Based on the application, the global market share was shadowed by cancer treatment previously. Since 2020, the global market share was dominated Covid-19 related treatments. However, cancer is anticipated to become the lead contributor during the forecast period. Get More Insight before Buying at: List of Key Players in Peptide Therapeutics Market: Teva Pharmaceutical Industries AstraZeneca Sanofi S.A Amazen Inc. Takeda Pharmaceutical Ipsen S.A Merck & Co. Novo Nordisk A/S GlaxoSmithKline plc Ever Neuro Pharma Eli Lilly and Company CordenPharma International Key questions answered in this report: What are the growth rate forecast and market size for Peptide Therapeutics Market? What are the key driving factors propelling the Peptide Therapeutics Market forward? What are the most important companies in the Peptide Therapeutics Market Industry? What segments does the Peptide Therapeutics Market cover? How can I receive a free copy of the Peptide Therapeutics Market sample report and company profiles? Report Scope: Free Brochure: Recent Developments: August 2019 witnessed the merger of Neoleukin Inc. and Aquinox Pharmaceuticals to invest in peptide therapeutics which are designed computationally. The firms intend to produce peptide-based drugs for diseases that currently do not have peptide therapeutics available for treatment. In June 2019, a collaboration between Gubra and Boehringer Ingelheim International was announced. The collaboration is intended to pave a way for newer peptide therapeutics drugs that will help in treating diabetes. Regional Dominance: North America to lead the global market during the forthcoming period. The global peptide therapeutics market is anticipated to be led by North America. This region is the hub of key pharmaceutical players, high technology, R&D investment capacity, and world-class cancer treatment facilities, making it a heavily contributing region in the global market. Europe is expected to show steady growth in the global market because of its advanced healthcare infrastructure and growing awareness related to peptide therapeutics. Asia-Pacific & the Middle East witnessed a rise in the global market because of Covid-19. Rising cancer, diabetes, and acute respiratory disorders along with increased healthcare investments are anticipated to assist the global market growth. Africa & Latin America are expected to grow slowly owing to a lack of information on peptide therapeutics along with an absence of necessary healthcare infrastructure, resources, and treatment facilities. Global Peptide Therapeutics Market is segmented as follows: Peptide Therapeutics Market: By Route of Administration Outlook (2022-2028) Parenteral Oral Others Peptide Therapeutics Market: By Type Outlook (2022-2028) Innovative Generic Peptide Therapeutics Market: By Type of Manufacturers Outlook (2022-2028) In-house Outsourced Peptide Therapeutics Market: By Type of Molecule Outlook (2022-2028) Vasopressin Somatostatin Calcitonin Immunopeptide Natriuretic Others Peptide Therapeutics Market: By Technology Outlook (2022-2028) Liquid phase Solid-phase Hybrid phase Peptide Therapeutics Market: By Application Outlook (2022-2028) Cancer Cardiovascular Disease Metabolic Disease Respiratory Disease Infectious Disease Others Peptide Therapeutics Market: By Region Outlook (2022-2028) North America The U.S. Canada Europe France The UK Spain Germany Italy Rest of Europe Asia Pacific China Japan India South Korea Southeast Asia Rest of Asia Pacific Latin America Brazil Mexico Rest of Latin America Middle East & Africa GCC South Africa Rest of Middle East & Africa Browse Other Related Research Reports from Zion Market Research Genomics Personalized Health Market - Global Industry Analysis : The global Genomics Personalized Health market accounted for USD 4,789.2 Million in 2020 and is expected to reach USD 6,649.2 Million by 2028, growing at a CAGR of 4.4% from 2021 to 2028. Medical Supply Delivery Service Market - Global Industry Analysis : The global Medical Supply Delivery Service Market accrued earnings worth approximately 49.1 (USD Billion) in 2020 and is predicted to gain revenue of about 104.2 (USD Billion) by 2028, is set to record a CAGR of nearly 10.2% over the period from 2021 to 2028. Healthcare Video Conferencing Solutions Market - Global Industry Analysis : The global Healthcare Video Conferencing Solutions Market accrued earnings worth approximately 76.1 (USD Million) in 2020 and is predicted to gain revenue of about 115.2 (USD Million) by 2028, is set to record a CAGR of nearly 4.8% over the period from 2021 to 2028. Browse through Zion Market Research's coverage of the Global Healthcare Industry Follow Us on: LinkedIn | Twitter | Facebook About Us Zion Market Research is an obligated company. We create futuristic, cutting edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client's needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us . Contact Us: Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States Tel: +49-322 210 92714 USA/Canada Toll Free No.1-855-465-4651 Email: [email protected] Website: Blog - SOURCE Zion Market Research

并购

100 项与广州呼吸疾病研究所相关的药物交易

登录后查看更多信息

100 项与广州呼吸疾病研究所相关的转化医学

登录后查看更多信息